Michelle V. Lihon
Research Subjects
Michelle V. Lihon has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Emily L. Danzeisen
Department of Biochemistry, Purdue University
2 shared publications - Kedric L. Milholland
Purdue University
2 shared publications - Mark C. Hall
Department of Biochemistry, Purdue University, West Lafayette, IN, USA
2 shared publications - Audrey F. Bates
Department of Biochemistry, Purdue University, West Lafayette, IN, USA
1 shared publication - Benjamin T. Waddey
Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA
1 shared publication Emma K. Seipp
Purdue University
1 shared publication
Latest Publications
- 10 September 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (10) , 2712-2724
Tideglusib as a First-in-Class Chemical Probe for NatA: Identification, Mechanism, and Cellular Validation of an Allosteric, CoA-Dependent Inhibitor
N-terminal acetyltransferase A (NatA) catalyzes 40–57% of eukaryotic Nα-acetylation, a co-translational modification critical for protein stability, localization, and function, yet no validated small-molecule probe of NatA has been reported. Here, we describe the discovery and characterization of tideglusib (YD3139), a clinical-stage GSK-3β inhibitor, as the first small-molecule probe for NatA through a unprecedented catalysis-dependent mechanism. This dual-event mechanism was established through intact protein MS, rapid dilution assays, and substrate-independent IC50 profiling. Tideglusib binds allosterically to Saccharomyces cerevisiae NatA (yNatA), whereupon the CoA released during catalysis chemically modifies tideglusib to form a reversible covalent adduct, a new paradigm for acetyltransferase inhibition. Tideglusib was identified by screening of an in-house library (∼700 compounds) and confirmed by structural optimization of the thiadiazolidinedione scaffold, yielding IC50 values of 0.68–1.8 μM against yeast and human NatA with >20-fold selectivity over other NAT family members. Quantitative proteomics confirmed on-target suppression of NatA-mediated Nα-acetylation in yeast. These findings establish tideglusib as a mechanistic chemical probe for NatA, reveal NatA as a previously unrecognized molecular target for a promiscuous clinical-stage investigational compound, and introduce a conceptual framework for exploiting catalysis-dependent adduct formation as a new strategy for acetyltransferase inhibitor design.
- 10 September 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (10) , 2712-2724
Tideglusib as a First-in-Class Chemical Probe for NatA: Identification, Mechanism, and Cellular Validation of an Allosteric, CoA-Dependent Inhibitor
N-terminal acetyltransferase A (NatA) catalyzes 40–57% of eukaryotic Nα-acetylation, a co-translational modification critical for protein stability, localization, and function, yet no validated small-molecule probe of NatA has been reported. Here, we describe the discovery and characterization of tideglusib (YD3139), a clinical-stage GSK-3β inhibitor, as the first small-molecule probe for NatA through a unprecedented catalysis-dependent mechanism. This dual-event mechanism was established through intact protein MS, rapid dilution assays, and substrate-independent IC50 profiling. Tideglusib binds allosterically to Saccharomyces cerevisiae NatA (yNatA), whereupon the CoA released during catalysis chemically modifies tideglusib to form a reversible covalent adduct, a new paradigm for acetyltransferase inhibition. Tideglusib was identified by screening of an in-house library (∼700 compounds) and confirmed by structural optimization of the thiadiazolidinedione scaffold, yielding IC50 values of 0.68–1.8 μM against yeast and human NatA with >20-fold selectivity over other NAT family members. Quantitative proteomics confirmed on-target suppression of NatA-mediated Nα-acetylation in yeast. These findings establish tideglusib as a mechanistic chemical probe for NatA, reveal NatA as a previously unrecognized molecular target for a promiscuous clinical-stage investigational compound, and introduce a conceptual framework for exploiting catalysis-dependent adduct formation as a new strategy for acetyltransferase inhibitor design.
- Open Access
Expansion and optimization of the auxin-inducible degron 2 (AID2) system in Candida pathogens
The auxin-inducible degron (AID) technology is a convenient and powerful tool for protein functional characterization in a broad array of eukaryotic species. We recently demonstrated that the original AID and improved AID2 systems are very effective at rapid protein depletion in Candida albicans and described a limited set of reagents for their use in certain auxotrophic lab strains. With an eye towards broader applicability with improved flexibility, we report here a new series of template vectors suitable for employing AID2 technology in prototrophic C. albicans strains, including clinical isolates. We adapted a common recyclable antibiotic marker system for the required genome editing steps and developed a strategy for simultaneous CRISPR/Cas9-mediated tagging of both target alleles. We also developed a composite all-in-one tagging cassette that combines the degron tag and the OsTIR1 F74A gene for single step strain engineering. We added a fluorescent protein tag option and designed and validated an approach for N-terminal tagging that retains natural promoter control. We also compared effectiveness of the two commonly used synthetic auxins, 5-Ph-IAA and 5-Ad-IAA and the two common OsTIR1 variants, F74A and F74G, and provide guidelines for using the new AID2 system. Finally, using the novel all-in-one cassette, we demonstrate that the AID2 system also works in Candida auris . The new reagents should enhance the convenience and accessibility of the AID2 system for the Candida research community. IMPORTANCE: Invasive fungal infections, including those caused by Candida species, are a persistent global health problem, and their treatment is hindered by limited antifungal options and the emergence of drug resistance. There is an urgent need for tools and methods to accelerate discovery of novel therapeutic targets. The expanded and optimized auxin-inducible degron system described herein provides a versatile platform for characterizing protein function and dissecting pathways governing important traits like virulence, stress tolerance, and antifungal resistance. The new reagents make AID technology applicable to any strain. Ultimately, this enhanced toolkit has the potential to help identify and validate new high-value drug targets and deepen our understanding of molecular mechanisms that drive pathogenicity of Candida and other fungal pathogen species.
Open AccessExpansion and optimization of the auxin-inducible degron 2 (AID2) system in Candida pathogens
The auxin-inducible degron (AID) technology is a convenient and powerful tool for protein functional characterization in a broad array of eukaryotic species. We recently demonstrated that the original AID and improved AID2 systems are very effective at rapid protein depletion in Candida albicans and described a limited set of reagents for their use in certain auxotrophic lab strains. With an eye towards broader applicability with improved flexibility, we report here a new series of template vectors suitable for employing AID2 technology in prototrophic C. albicans strains, including clinical isolates. We adapted a common recyclable antibiotic marker system for the required genome editing steps and developed a strategy for simultaneous CRISPR/Cas9-mediated tagging of both target alleles. We also developed a composite all-in-one tagging cassette that combines the degron tag and the OsTIR1 F74A gene for single step strain engineering. We added a fluorescent protein tag option and designed and validated an approach for N-terminal tagging that retains natural promoter control. We also compared effectiveness of the two commonly used synthetic auxins, 5-Ph-IAA and 5-Ad-IAA and the two common OsTIR1 variants, F74A and F74G, and provide guidelines for using the new AID2 system. Finally, using the novel all-in-one cassette, we demonstrate that the AID2 system also works in Candida auris . The new reagents should enhance the convenience and accessibility of the AID2 system for the Candida research community. IMPORTANCE: Invasive fungal infections, including those caused by Candida species, are a persistent global health problem, and their treatment is hindered by limited antifungal options and the emergence of drug resistance. There is an urgent need for tools and methods to accelerate discovery of novel therapeutic targets. The expanded and optimized auxin-inducible degron system described herein provides a versatile platform for characterizing protein function and dissecting pathways governing important traits like virulence, stress tolerance, and antifungal resistance. The new reagents make AID technology applicable to any strain. Ultimately, this enhanced toolkit has the potential to help identify and validate new high-value drug targets and deepen our understanding of molecular mechanisms that drive pathogenicity of Candida and other fungal pathogen species.
- Open Access
- 8 August 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (9) , 107644
Cdc14 phosphatases use an intramolecular pseudosubstrate motif to stimulate and regulate catalysis
- 8 August 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (9) , 107644
Open AccessCdc14 phosphatases use an intramolecular pseudosubstrate motif to stimulate and regulate catalysis